Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry P Erba

Showing results (41-50 of 123) with videos related to

Pageof 13
Sort By:
Blood Advances|June 30, 2019
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemiaHarry P Erba, Pamela S Becker, Paul J Shami, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133Patricia A Ganz, Carol M Moinpour, Donna K Pauler, et al.
Leukemia|October 14, 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsMegan Othus, Elihu H Estey, Guillermo Garcia-Manero, et al.
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Pageof 13

Showing results (41-50 of 123) with videos related to

Sort By:
Pageof 13
Blood Advances|June 30, 2019
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemiaHarry P Erba, Pamela S Becker, Paul J Shami, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133Patricia A Ganz, Carol M Moinpour, Donna K Pauler, et al.
Leukemia|October 14, 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsMegan Othus, Elihu H Estey, Guillermo Garcia-Manero, et al.
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Pageof 13